Gómez-De LA, Alvarado-Navarro DM, Rodríguez-Zúñiga AC, Coronado-Alejandro EU

Language: Spanish
References: 11
Page: s107-110
PDF size: 108.49 Kb.

REFERENCES

1. Yu JX, Upadhaya S, Tatake R et al. Cancer cell therapies: the clinical trial landscape. Nat Rev Drug Discov. 2020; 19 (9): 583-584.

2. Schuster SJ, Svoboda J, Chong EA et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017; 377 (26): 2545-2554.

3. Gardner RA, Finney O, Annesley C et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017; 129 (25): 3322-3331.

4. Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in universal CAR-T cell therapy. Front Immunol. 2021; 12: 744823.

5. Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019; 34: 45-55.

6. Lin JK, Lerman BJ, Barnes JI et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol. 2018; 36 (32): 3192-3202.

7. Singh N, Orlando E, Xu J et al. Mechanisms of resistance to CAR T cell therapies. Semin Cancer Biol. 2020; 65: 91-98.

8. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016; 126 (6): 2123-2138.

9. Ortíz-Maldonado V, Rives S, Castella M et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed/refractory malignancies. Mol Ther. 2021; 29 (2): 636-644.

10. Depil S, Duchateau P, Grupp SA et al. "Off-the-shelf" allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020; 19 (3): 185-199.

11. Biederstadt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. Int J Hematol. 2021; 114: 554-571.